Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 1.00 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15815783 | 0.85 | BRD4 (0.81) | BRD4EP300CREBBPHDAC6 | |
| SCHEMBL15815586 | 0.84 | BRD4 (0.80) | BRD4EP300CREBBPPTGDR2 | |
| SCHEMBL17844281 | 0.84 | BRD4 (1.00) | BRD4EP300CREBBPPTGDR2 | |
| SCHEMBL17844303 | 0.83 | BRD4 (0.71) | BRD4EP300CREBBPKDM1AHDAC6 | |
| SCHEMBL23174934 | 0.83 | BRD4 (0.78) | BRD4EP300CREBBP | |
| SCHEMBL28939035 | 0.83 | BRD4 (0.78) | BRD4EP300CREBBP | |
| SCHEMBL15816714 | 0.83 | BRD4 (0.78) | BRD4EP300CREBBPHDAC6PTGDR2 | |
| SCHEMBL15815772 | 0.83 | BRD4 (1.00) | BRD4EP300CREBBPPTGDR2 | |
| Hydrochloric Acid SCHEMBL29520756 | 0.82 | BRD4 (0.76) | BRD4EP300CREBBP | |
| SCHEMBL15815001 | 0.82 | BRD4 (0.80) | BRD4EP300CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| CN-107406438-B | Inhibitors of bromodomains | 恒翼生物医药科技(上海)有限公司 | 2021-05-14 | — | — | CN | claimed |
| US-10231953-B2 | Inhibitors of bromodomains | ZENITH EPIGENETICS LTD. (CA) | 2019-03-19 | — | — | US | claimed |
| US-20170360760-A1 | Inhibitors of Bromodomains | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | claimed |
| US-11938164-B2 | Exosome-based cancer assays | TRUSTEES OF BOSTON UNIVERSITY | 2024-03-26 | — | — | US | disclosed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20220331390-A1 | EXOSOME-BASED CANCER ASSAYS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-10-20 | — | — | US | disclosed |
| WO-2022216765-A1 | EXOSOME-BASED CANCER ASSAYS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-107406438-B | Inhibitors of bromodomains | 恒翼生物医药科技(上海)有限公司 | 2021-05-14 | — | — | CN | disclosed |
| US-10231953-B2 | Inhibitors of bromodomains | ZENITH EPIGENETICS LTD. (CA) | 2019-03-19 | — | — | US | disclosed |
| US-10231953-B2 | Inhibitors of bromodomains | ZENITH EPIGENETICS LTD. (CA) | 2019-03-19 | — | — | US | disclosed |
| US-20170360760-A1 | Inhibitors of Bromodomains | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| US-20170360760-A1 | Inhibitors of Bromodomains | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| US-20170360760-A1 | Inhibitors of Bromodomains | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| EP-3233846-A1 | INHIBITORS OF BROMODOMAINS | Zenith Epigenetics Ltd. (CA) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097863-A1 | INHIBITORS OF BROMODOMAINS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360760-A1 | Inhibitors of Bromodomains | BRDT, BRD3, BRPF3 | BRD4 5/4885EP300 13/4885CREBBP 43/4885 |
| US-10231953-B2 | Inhibitors of bromodomains | BRDT, BRD3, BRPF3 | BRD4 5/4885EP300 13/4885CREBBP 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.